亚盛医药(06855.HK)抗耐药白血病新药临床进展再入选美国血液学会年会口头报告
亚盛医药(06855.HK)公布,公司的原创1类新药新型BCR-ABL抑制剂HQP1351(拟定中文通用名:奥瑞巴替尼)的关键性注册II期临床研究结果入选第62届美国血液学会(American Society of Hematology (ASH))年会的口头报告。
北京大学人民医院血液科两教授黄晓军和江倩是研究的主要研究者,江倩将在会议期间作此报告。这是继2018、2019年之後,HQP1351的临床进展第三次入选ASH年会口头报告。连续三年入选,充分显示了国际血液学界对HQP1351疗效和安全性的认可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.